Prevalence of etiological factors and Ayurvedic outcome in Ekakushtha (psoriasis)

Prevalence of Shonita Dushti Nidana in Ekakushtha (psoriasis) and Upashayatmaka effect of Sarivadi Gana in its treatment-An open labelled single arm study.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030831

Enrollment

100

Registered

2021-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

Intervention1: Sarivadi Gana: Drug:Sarivadi Gana (sariva,Yashtimadhu,Chandan,Raktachandan, Padmak Kashmari phal, Madhuk pushpa,Usheer) Dose: 6gms two times a day with normal water. Duration: 30 days.

Eligibility

Inclusion criteria

Inclusion criteria: 1.Cases having clinical features of Ekakushtha (Psoriasis). 2.Cases willing to participate in study with age group of 18-60yrs irrespective of their gender, religion, economic status. 3.Diagnosed cases of mild to moderate psoriasis (on the basis of BSA and PASI score) for interventional study.

Exclusion criteria

Exclusion criteria: 1.Cases with severe systemic disorders. 2.Pregnant women and lactating mother.

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms in patients of Ekakushtha. Timepoint: 30 days	—

Secondary

Measure	Time frame
Improvement in quality of life and will be assessed by dermatology life quality indexTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Shalini Rai

All India Institute of Ayurveda

drmoreanand@gmail.com8830389544

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026